This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    VIP943
Previous Study | Return to List | Next Study

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06034275
Recruitment Status : Recruiting
First Posted : September 13, 2023
Last Update Posted : January 12, 2024
Sponsor:
Information provided by (Responsible Party):
Vincerx Pharma, Inc.

Brief Summary:
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia B-cell Acute Lymphoblastic Leukemia High-risk Myelodysplastic Syndrome Drug: VIP943 Phase 1

Detailed Description:
Relapsed or refractory AML, MDS, or B-ALL subjects who are CD123 positive. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
Actual Study Start Date : September 13, 2023
Estimated Primary Completion Date : May 30, 2025
Estimated Study Completion Date : December 31, 2025


Arm Intervention/treatment
Experimental: Dose Escalation of VIP943
Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration weekly (QW).
Drug: VIP943
VIP943 will be administered by IV Infusion weekly




Primary Outcome Measures :
  1. Incidence of DLT (Dose limit toxicity) of VIP943 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days ]

Secondary Outcome Measures :
  1. Response rate to VIP943 as assessed by investigators using disease-specific response criteria [ Time Frame: Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 28 days (up to approximately 10 months) ]
  2. Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of VIP943 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days ]
  3. Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of VIP943 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 28 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed AML, B-ALL or MDS. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.
  • Evidence of ≥5% bone marrow or blood blasts (acute leukemia) or ≥5% bone marrow or blood myeloblasts (MDS) to allow for assessment of drug activity.
  • Evidence of CD123 expression from a local laboratory.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

Exclusion Criteria:

  • Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Clinically significant cardiac disease including congestive heart failure > New York Heart Association (NYHA) Class II), evidence for coronary artery disease (eg, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months or myocardial infarction within the past 6 months before first dose.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06034275


Contacts
Layout table for location contacts
Contact: Vincerx Clinical Trials Contact 16508006676 clinicaltrials@vincerx.com

Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35233
Contact: Research Site         
United States, Ohio
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Research Site         
United States, Tennessee
TriStar Bone Marrow Transplant Recruiting
Nashville, Tennessee, United States, 37203
Contact: Research Site         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Research Site         
Sponsors and Collaborators
Vincerx Pharma, Inc.
Investigators
Layout table for investigator information
Study Director: Vincerx Study Director Vincerx Pharma, Inc.
Layout table for additonal information
Responsible Party: Vincerx Pharma, Inc.
ClinicalTrials.gov Identifier: NCT06034275    
Other Study ID Numbers: VNC-943-101
First Posted: September 13, 2023    Key Record Dates
Last Update Posted: January 12, 2024
Last Verified: January 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Vincerx Pharma, Inc.:
ADC
Hematologic Malignancies
Leukemia
CD123
B-ALL
AML
MDS
Relapsed/ Refractory
Hematologic Diseases
Bone Marrow Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Neoplasms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hematologic Neoplasms
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Leukemia, Lymphoid
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms by Site